Orphanet Journal of Rare Diseases

Open accessIn DOAJFee waivers availableBiochemistry, Genetics and Molecular Biology

Orphanet Journal of Rare Diseases is published by BioMed Central as an open access journal (ISSN 1750-1172). The list article processing charge is $2,990. Typical time to publication is 16 wks. Its OpenAlex h-index is 181. Primary field: Biochemistry, Genetics and Molecular Biology. It is listed in the Directory of Open Access Journals. Fee waivers are stated as available. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.

Cost to publish

$2,990

Open-access article processing charge, list price.

Checked · Journal fee page

Time to publication

16 wks

Broadly typical for the field.

h-index

181

OpenAlex citation statistic. Not a Journal Impact Factor.

2-year mean citedness

3.1

Average citations to articles from the previous two years.

What it costs to publish here

Publishing an open-access article in Orphanet Journal of Rare Diseases is listed at $2,990. The publisher also lists 2,490 EUR, 2,190 GBP. The journal reports that fee waivers are available — worth pursuing if you are funding this yourself or working from a lower-income country.

The journal's own fee page →

What this journal has charged over time

List price for an open-access article in Orphanet Journal of Rare Diseases, as recorded by OpenAlex for each year. The fee has risen 16% since 2019, from $2,570 to $2,990.

$0$1.5k$3k2019: $2,57020192020: $2,68020202021: $2,68020212022: $2,68020222023: $2,79020232024: $2,89020242025: $2,9902025

Publishers change list prices without notice and often apply discounts, institutional agreements or waivers. Treat this as the trend, and confirm the current figure with the journal.

Peer review and licensing

Review modelAnonymous peer review (policy)
LicenceCC BY, CC0
Author keeps copyrightYes
Plagiarism screeningYes
Editorial boardPublished →
LanguagesEN

Verification checks

8 of 8 confirmed

These are facts we could verify in public records, not a verdict. A journal missing a check is not necessarily disreputable — many long-established subscription journals sit outside the open-access registries entirely. Use them as questions to ask, and confirm anything that matters directly with the journal before you submit.

  • Listed in the Directory of Open Access JournalsDOAJ applies a documented set of inclusion criteria.Confirmed
  • Included in OpenAlex's curated core setOpenAlex flags well-established venues that appear across major indexes.Confirmed
  • Peer review model publicly declaredAnonymous peer reviewConfirmed
  • Publication charges stated up frontA journal that will not tell you the fee before submission is worth a second look.Confirmed
  • Screens submissions for plagiarismReported to DOAJ by the journal.Confirmed
  • Participates in a digital preservation schemeArchiving means the record survives if the publisher does not.Confirmed
  • Assigns persistent identifiers (DOIs)Standard practice; its absence is unusual.Confirmed
  • Still actively publishingMost recent indexed article: 2026.Confirmed

Scope

The subjects Orphanet Journal of Rare Diseases publishes most, derived from the topics assigned to its indexed articles.

Genomics and Rare DiseasesLysosomal Storage Disorders ResearchMetabolism and Genetic DisordersGlycogen Storage Diseases and MyoclonusHealth Systems, Economic Evaluations, Quality of LifeConnective tissue disorders researchNeurogenetic and Muscular Disorders ResearchMitochondrial Function and PathologyGenetic Neurodegenerative DiseasesAmyloidosis: Diagnosis, Treatment, Outcomes

Publication record

Indexed articles5,434
Total citations188,059
i10-index3,018
Most recent indexed article2026
Open access since2006
All ISSNs1750-1172

Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.